Horizon Therapeutics Public Stock Forecast for 2023 - 2025 - 2030
Updated on 11/29/2023
Horizon Therapeutics Public Stock Forecast and Price Target
Horizon Therapeutics Public's stock price reaches the average target of $63.61 by 2024 as expected recently by six notable experts, there would be a potential downside of approximately -45.02% from the last closing price in September, 2023. This possible increase is based on a high estimate of $71.24 and a low estimate of $56.61. Even if you are not interested in HZNP stock, it is still imperative to be aware of its competitors.
-45.02% Downside
Horizon Therapeutics Public Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's Price has grown, increasing from $32.26 to $82.98 – a growth of 157.22%. According to 0 prominent analysts, Horizon Therapeutics Public's Fair Value will fall by 24.48% in the next year, reaching $62.67. By 2030, professionals believe that Horizon Therapeutics Public's Fair Value will decrease by 14.77%, reaching $70.73 – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
10
|
kr687.90 | Buy/Sell | kr696.07 | 12.30% |
| ABBV Stock Forecast | AbbVie | Outperform |
10
|
$138.08 | Buy/Sell | $167.35 | 20.94% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
10
|
$102.06 | Buy/Sell | $116.25 | 12.97% |
| 4502 Stock Forecast | Takeda Pharmaceutical Company | Outperform |
16
|
¥4.19k | Buy/Sell | ¥0.00 | 12.31% |
| A Stock Forecast | Agilent Technologies | Outperform |
17
|
$124.71 | Buy/Sell | $132.86 | 8.25% |
Horizon Therapeutics Public Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's Revenue has grown, increasing from $1.30B to $3.63B – a growth of 179.15%. According to 0 prominent analysts, Horizon Therapeutics Public's Revenue will fall by 27.94% in the next year, reaching $2.62B. By 2030, professionals believe that Horizon Therapeutics Public's Revenue will decrease by 19.28%, reaching $2.93B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BIIB Stock Forecast | Biogen Inc | Outperform |
11
|
$227.41 | Buy/Sell | $322.44 | 36.76% |
| ILMN Stock Forecast | Illumina Inc | Outperform |
16
|
$96.54 | Buy/Sell | $254.08 | 45.02% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$9.14 | Buy/Sell | $11.74 | 25.82% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 500124 Stock Forecast | Dr. Reddy's Laboratories | Outperform |
18
|
Rp5.64k | Buy/Sell | Rp5.47k | 3.03% |
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$114.49 | Buy/Sell | $0.00 | 72.07% |
| ALKS Stock Forecast | Alkermes | Outperform |
10
|
$23.55 | Buy/Sell | $0.00 | 44.37% |
Horizon Therapeutics Public Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's Free Cash Flow has grown by 192.26%, rising from $408.47M to $1.19B. In the next year, 0 analysts estimate that Horizon Therapeutics Public's Free Cash Flow will decrease by 29.22%, reaching $845.02M. According to professional forecasts, in 2030, Horizon Therapeutics Public's Free Cash Flow will decrease by 23.84%, reaching $909.15M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4403 Stock Forecast | NOF | Buy |
18
|
¥6.87k | Buy/Sell | ¥0.00 | 10.59% |
| RVNC Stock Forecast | Revance Therapeutics | Outperform |
6
|
$7.06 | Buy/Sell | $38.55 | 289.52% |
| ASRT Stock Forecast | Assertio Holdings | Buy |
8
|
$1.15 | Buy/Sell | $6.75 | 247.83% |
Horizon Therapeutics Public Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's Net Income has seen a drop from $573.02M to $521.48M – a 8.99% decrease. Next year, analysts are expecting Net Income to reach $560.45M – an increase of 7.47%. Professionals believe that By 2030, Horizon Therapeutics Public's Net Income will fall to $518.96M– a 0.48% decrease from its current value.
Horizon Therapeutics Public EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's EBITDA has grown by 480.23%, rising from $145.40M to $843.66M. According to 0 analysts, Horizon Therapeutics Public's EBITDA will fall by 37.21% in the next year, reaching $529.71M. Professionals believe that By 2030, Horizon Therapeutics Public's EBITDA will fall to $660.55M – a 21.70% decrease from its current value.
Horizon Therapeutics Public EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's EBIT has grown, rising from $138.66M to $819.73M – a growth of 491.18%. In the following year, 0 experts forecast that Horizon Therapeutics Public's EBIT will decrease by 37.66%, to $511.02M. In 2030, professionals predict that Horizon Therapeutics Public's EBIT will decrease by 21.92%, to $640.04M.
Horizon Therapeutics Public EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Horizon Therapeutics Public's EPS has grown, increasing from $1.94 to $4.99 – a growth of 157.22%. According to 0 prominent analysts, Horizon Therapeutics Public's EPS will fall by 24.48% in the next year, reaching $3.77. By 2030, professionals believe that Horizon Therapeutics Public's EPS will decrease by 14.77%, reaching $4.25 – a concerning trend for the company.
Site Navigation
.jpg)